Evidence map›Paper›PMID 25607111›Full record

ArticleOncology reports2015

Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma.

Tao Xu, Bojin Su, Chunhua Wang, Sumei Wang, Hecheng Huang, Yunbao Pan, Donghui Wang, Weihong Wei, François X Claret, Huiling Yang

Open access · bronzeAbstract read
In one paragraph

Article in Oncology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. The emerging roles of Jab1/CSN5 in cancer.Medical oncology (Northwood, London, England) · 2016
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Jab1/Cops5: a promising target for cancer diagnosis and therapy.International journal of clinical oncology · 2021
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Tao XuDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, Guangzhou 510600, P.R. China.
Bojin SuDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, Guangzhou 510600, P.R. China.
Chunhua WangDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, Guangzhou 510600, P.R. China.
Sumei WangDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, Guangzhou 510600, P.R. China.
Hecheng HuangDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, Guangzhou 510600, P.R. China.
Yunbao PanDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, Guangzhou 510600, P.R. China.
Donghui WangDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, Guangzhou 510600, P.R. China.
Weihong WeiDepartment of Radiation Oncology, First People's Hospital of Foshan, Guangdong, Foshan 528000, P.R. China.
François X ClaretDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Huiling YangDepartment of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, Guangzhou 510600, P.R. China.
Sun Yat-sen University · CNFirst People's Hospital of Foshan · CNThe University of Texas MD Anderson Cancer Center · US

Funding

Targeting JAB1 Oncogenic Function in Breast CancerR01CA090853 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CLARET, FRANCOIS X · 2002 to 2011
$2.5M
NCI NIH HHS R01 CA090853NCI NIH HHS R01-CA90853
6 · The paper itself

Abstract

An important challenge in nasopharyngeal carcinoma (NPC) research is to develop effective predictors of tumor recurrence following treatment to determine whether immediate adjuvant therapy is necessary. We retrospectively analyzed archived specimens collected from 45 patients with paired samples of primary NPC (pNPC) and recurrent NPC (rNPC). Clinical samples were collected from the Cancer Center Databases of the First People's Hospital of Foshan and Shantou Central Hospital (affiliates of Sun Yat-Sen University) between 2001 and 2012. Expression levels of phosphor-Stat3 (p-Stat3), signalosome complex subunit 5 (Jab1/Csn5), Akt1, C/EBP homologous protein (CHOP), Ki-67, and apoptosis were determined by immunohistochemistry in pNPC and rNPC samples from the same patients. Differences in these markers between the short-term interval to recurrence (ITR) group (ITR <18 months) and long-term ITR group (ITR ≥18 months) were further analyzed. In Cox's regression analysis, the ITR was significantly associated as an independent‑negative prognostic factor for overall survival (hazard ratio, 0.211; 95% confidence interval, 0.053-0.841; P=0.027). p-Stat3 was increased in the short-term ITR group (ITR <18 months) and tended to be lower in the long-term ITR group (ITR ≥18 months). In the short-term ITR group, nuclear Akt expression was significantly increased in paired rNPC (P=0.028). In the long-term ITR group, the expression of nuclear Jab1/Csn5 (P=0.047) and assessment of apoptosis measured with TdT-mediated dUTP nick end‑labeling (TUNEL) (P=0.003) was significantly increased in paired rNPC. The results suggest that differences between short- and long-term ITR may predict outcome in rNPC. Furthermore, the overexpression of Jab1/Csn5 and Akt may contribute to the carcinogenesis of rNPC, and Akt seems to promote the progression of short-term ITR. Intra-individual changes of Jab1/Csn5, Akt, and TUNEL may help to identify short-term ITR.

Indexed as

ApoptosisBiomarkers, TumorCarcinomaCOP9 Signalosome ComplexFemaleHumansIn Situ Nick-End LabelingIntracellular Signaling Peptides and ProteinsKi-67 AntigenMaleMiddle AgedNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalPeptide HydrolasesPrognosisAKT1 protein, humanBiomarkers, TumorCOP9 Signalosome ComplexCOPS5 protein, humanDDIT3 protein, humanIntracellular Signaling Peptides and ProteinsKi-67 AntigenPeptide HydrolasesProto-Oncogene Proteins c-aktSTAT3 protein, humanSTAT3 Transcription FactorTranscription Factor CHOP

Identifiers

PMID25607111
PMCPMC4324483
OpenAlexW2027606772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.